Dr. Michael Rome joined Foresite Capital in 2016 and leads the therapeutics investing practice. Michael has led numerous investments including: XinThera (acquired by Gilead Sciences), Affinivax (acquired by GSK), Turning Point Therapeutics (acquired by BMS), Pharvaris (Nasdaq: PHVS), Nurix (Nasdaq: NRIX), CG Oncology (Nasdaq: CGON) and Alumis where he led the acquisition of Fronthera Biopharma. He currently serves as a board director at numerous portfolio companies and directs the investment activities for all biopharma and therapeutics companies at the firm. Prior to Foresite Capital, he was an analyst at DAFNA Capital Management, covering therapeutics companies. He earned a BS in Molecular, Cell, and Developmental Biology from UCLA and obtained his PhD in Biochemistry at Caltech as an NSF Fellow.
